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Intestinal absorptionAbstract Objective: Candesartan cilexetil (CAN) is a poor aqueous soluble compound and a
P-glycoprotein (P-gp) efﬂux pump substrate. These key factors are responsible for its incomplete
intestinal absorption.
Methods: In this study, we investigated to enhance the absorption of CAN by improving its sol-
ubility and inhibiting intestinal P-gp activity. A phase solubility method was used to evaluate the
aqueous solubility of CAN in PVP K30 (0.2–2%). Gibbs free energy ðDGotrÞ values were all negative.
Solubility was enhanced by the freeze drying technique. The in vitro dissolution was evaluated using
the USP paddle method. The interaction between drug and carrier was evaluated by Fourier trans-
form infrared spectroscopy (FTIR), X-ray diffraction (XRD) and Differential scanning calorimetry
(DSC) studies. Naringin was selected as P-gp inhibitor. Absorption studies were performed using
the everted gut sac model from rat jejunum. The drug analysis was performed by HPLC.
Results: FTIR spectra revealed no interaction between drug and PVP K30. From XRD and DSC
data, CANwas in the amorphous form, which explains the cumulative release of drug from its prepared
systems.WenoticedanenhancementofCANabsorptionby improving its solubilityand inhibiting theP-
gp activity. The signiﬁcant results (p< 0.05) were obtained for freeze dried solid dispersions in the pres-
ence of P-gp inhibitor than without naringin (15 mg/kg) with an absorption enhancement of 8-fold.
Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs 247Conclusion: Naringin, a natural ﬂavonoid, has no undesirable side effects. Therefore, it could be
employed as an excipient in the form of solid dispersions to increase CAN intestinal absorption
and its oral bioavailability.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Candesartan cilexetil (CAN) is an antihypertensive angiotensin
II receptor blocker, is rapidly and completely biaoactivated by
ester hydrolysis at the ester link to form the active candesartan
during absorption from the gastrointestinal (GI) tract McCle-
llan and Goa, 1998. Oral administration of CAN shows low
bioavailability, approximately 15% in humans, due to its low
water (pKa 6.0) solubility (Vijaykumar et al., 2009) and efﬂux
by drug resistance pumps in the gastrointestinal tract, limiting
the oral absorption (Zhang et al., 2012; Lee et al., 2009;
Kamiyama et al., 2010; Zhou et al., 2009). To overcome these
problems, a solid dispersion approach can be utilized to in-
crease the permeability (Shaikh and Avachat, 2011) and the
dissolution rate of highly lipophilic drugs thereby improving
their bioavailability (Arias et al., 1994; Zerrouk et al., 2001;
Palmieri et al., 2002; Lee et al., 2005). Usually, solid disper-
sions are two-component systems in which the drug is incorpo-
rated in the hydrophilic carrier. The drug within the
hydrophilic carrier may be dispersed molecularly or occur as
amorphous components. The improved dissolution of the drug
can be attributed to (i) enhanced solubility owing to its amor-
phous state or nano-particles (Kelvin’s law) Yonemochi et al.,
1997; Yonemochi et al., 1999; Mura et al., 2002; Dai et al.,
2007 (ii) increased surface area of nano particles of the drug
for drug dissolution (Kubo and Mizobe, 1997; Purvis et al.,
2006) and (iii) improved wetting caused by the hydrophilic car-
rier (Kawashima et al., 1975; Chow et al., 1995). Among all
hydrophilic carriers, Polyvinylpyrrolidone (PVP) is the most
often studied hydrophilic polymeric carriers (Janssens et al.,
2008; Shah et al., 2009; Gupta et al., 2004).
Interaction of various sartans with PVP K30 was investi-
gated in solution and in solid state. For example, solid disper-
sions with PVP K30 were found to improve the solubility and
enhance the dissolution rate of valsartan, compared with b-CD
and hydroxypropyl b-CD inclusion complexes. Freeze-dried
valsartan/PVP K30 (1:5 M ratio) solid systems offer rapid dis-
solution proﬁles in comparison with the proﬁles of valsartan
and its physical mixture with PVP K30 (Mahapatra et al.,
2011). The effect of water-soluble polymers (PEG 4000 or
PVP K-90) as a third component on the complexation of irbe-
sartan with b-CD was investigated. The study revealed that the
binding and the solubility were enhanced in the presence of the
third component (PVP K-90 at 5%) in comparison with the
binary system of irbesartan and b-CD (Rajashree et al., 2009).
Intestinal absorption is another key factor for the bioavail-
ability of oral dosage forms (Chillistone and Hardman, 2011).
It is well-known that inﬂux and efﬂux transporters such as P-
glycoprotein (P-gp) expressed on the membrane of epithelial
intestinal cells have a substantial impact on drug absorption.
Inﬂux transporters facilitate drug absorption, whereas efﬂux
transporters prevent the drug absorption (Scherrmann, 2009).
P-gp alters intestinal permeation of hydrophobic com-
pounds by averting the inﬂux into cells and facilitates drugefﬂux from intestinal cells back into the lumen. Inhibiting P-
gp may improve drug absorption across intestinal barriers
(Ishikawa et al., 2004; Linardi and Natalini, 2006; Kim,
2002). P-gp inhibitors act as high avidity substrates (e.g. verap-
amil, quinidine) or block its function by binding to it (e.g. sulf-
hydryl-substituted purine) (Fo¨ger, 2009).
These two key factors (poor water solubility and P-gp efﬂux
pumps) are well known for incomplete absorption of orally
administered drugs and thus limit their bioavailability (Streu-
bel et al., 2006; Dahan and Amidon, 2009).
Therefore; still it is a real problem to improve the intestinal
absorption and the oral bioavailability of candesartan cilexetil
though Nekkanti et al. and Gao et al. reported that the oral
bioavailability of candesartan was improved about 1.5-fold
and 10-fold by nanosuspension (Nekkanti et al., 2009) and
nanoemulsion (Gao et al., 2011) respectively until today. How-
ever, no reports showed the use of naringin as a pharmaceuti-
cal excipient in the presence of candesartan solid dispersions to
increase candesartan intestinal absorption and therefore its
oral bioavailability till today.
This study was intended to investigate the inﬂuence of the
manufacturing process used to prepare glassy materials on
the physicochemical properties of the products. Parameters
of particular importance were product homogeneity, dissolu-
tion, physical stability, and drug/polymer interactions. The fol-
lowing study constraints were applied to allow comparisons to
be made between manufacturing techniques. Only one poly-
mer, poly(vinylpyrrolidone) K30 (PVP), was selected for use
with all three manufacturing techniques. PVP was selected as
it has high aqueous solubility, a high glass transition tempera-
ture, is miscible with a range of poorly soluble drugs, and
forms hydrogen bonds with certain drugs (Forster et al.,
2001). Hydrogen bonding is widely recognized as an important
mechanism to increase amorphous stability (Matsumoto and
Zograﬁ, 1999). All products were prepared at a drug/PVP ratio
of 1:2 (w/w) as this was suitable for processing using all three
manufacturing techniques. The poorly soluble compound se-
lected was candesartan cilexetil (Patterson et al., 2005). There-
fore, in this study an attempt was made to enhance
candesartan cilexetil intestinal absorption by improving its sol-
ubility as solid dispersions with hydrophilic carrier (PVP K30)
using different pharmaceutical interventions and inhibiting the
intestinal efﬂux transporters, P-gp using naringin. Permeability
studies were conducted using the in vitro everted sac technique.
2. Materials and methods
2.1. Materials
Candesartan cilexetil (purity more than 99%, melting tempera-
ture = 163 ± 0.5 C) was kindly donated as a generous gift by
Dr. Reddy’s Labs, (Hyderabad, India). Polyvinyl pyrrolidone
K30 (PVP-K30) was supplied by SDFine Chem. Ltd.,Mumbai,
India. Naringin, Na2HPO4, KH2PO4, NaOH, KCl, citric acid
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Aldrich (Hyderabad, India). Other chemicals used were of ana-
lytical grade.All drug solutionswere freshlypreparedbeforeuse.
2.2. Phase solubility study
Phase solubility studies were performed as described by Higu-
chi and Connors (Higuchi and Connors, 1965). Pure drug
(CAN), in amounts that exceeded its solubility, was added to
a sequence of stoppered conical ﬂasks with 25 ml of aqueous
PVP-K30 solutions of various concentrations (0.2–2%) in dou-
ble distilled water and shaken for 48 h on a rotary ﬂask shaker.
After reaching equilibrium, the samples were ﬁltered through a
0.45 lm ﬁlter paper, suitably diluted with double distilled
water and assayed for the drug content at kmax of 255 nm using
a UV spectrophotometer (Shimazdu-1601, Shimazdu Corp,
Kyoto, Japan) against a blank prepared using the same con-
centration of PVP-K30 in double distilled water. All assays
were carried out at room temperature in triplicate.
2.3. Buffer Solution phosphate pH 6.8
77.3 ml of disodium phosphate R (71.5 g/l) was mixed with
22.7 ml of citric acid solution R (21 g/l).
2.4. Buffer solution phosphate pH 7.4
250 ml of potassium phosphate was added to 393.4 ml of
NaOH (0.1 M).
2.5. Preparation of physical mixture and solid dispersion
2.5.1. Physical mixtures
Physical mixtures of candesartan cilexetil (1:2 w/w) were pre-
pared by pulverization using a sample mill (SK-M2 model, To-
kyo, Japan) with polyvinyl pyrrolidone K30 as a carrier and
screened through a 60 mesh sieve. The physical mixtures con-
taining drug to carrier proportions (1:2 w/w) were mixed man-
ually with the appropriate amount of pure drug and carrier in
a ceramic bowl using a polymeric spatula until a homogeneous
mixture was obtained. The samples were screened through a 60
mesh sieve and then stored in a desiccator until further study.
Optical microscopy and sieve analysis indicated that all the
physical mixtures had similar particle sizes (mean particle size
150 and 250 lm diameter, n= 50).
2.5.2. Kneading method
The mixture of candesartan cilexetil (4 g) and PVP-K30 (8 g)
was wetted (in portions) with water (4 ml) and kneaded thor-
oughly for 30 min in a glass mortar. The homogeneous paste,
so formed was dried in an oven at 40 C vacuum for 24 h.
Dried powder was screened through a 60 mesh sieve and stored
in a desiccator until further study. Optical microscopy and
sieve analysis indicated that all the solid dispersions had simi-
lar particle sizes (mean particle size was between 150 and
250 lm diameter, n= 50).
2.5.3. Spray drying method (SPD)
The solid dispersions of CAN were prepared by evaporation of
a hydro-alcoholic solution of CAN and PVP K30 in optimizedratio (1:2 w/w) using a spray dryer (Buchi B-191, India). The
solution was prepared by dissolving 1 g of CAN in 50 ml of
methanol and 2 g of PVP K30 in 100 ml of distilled water
and mixing both solutions, which produce a clear solution.
The solvent was evaporated at the following sets of conditions:
air ﬂow rate at 500 l/h, under an atomization pressure of 2 kg/
cm2 with a solution ﬂow rate of 4 mL/min. The inlet tempera-
ture: 120 C and outlet temperature 90 C. The spray-dried
products were dried in a vacuum oven over a desiccant at
40 C for 24 h. The product thus obtained was screened
through a 60 mesh sieve, doubly wrapped in aluminum foil
and stored in a desiccator until further use. Optical microscopy
and sieve analysis indicated that all the solid dispersions had
similar particle sizes (mean particle size was between 150 and
250 lm diameter, n= 50).2.5.4. Freeze-drying method (FD)
Physical mixtures of drug (1:2 w/w, 20 g) and PVP-K30 (40 g)
were added to 500 ml of double distilled water and placed on a
mechanical shaker for 5 days. The resultant solution was pre-
pared by dissolving 1 g of CAN in 50 ml of methanol and 2 g
of PVP K30 in 100 ml of distilled water and mixing both solu-
tions, which produce a clear solution. The solvent was then
evaporated in vacuum at 50 C with a rotary evaporator.
The samples thus obtained were ground and sieved through
a (<38 lm) mesh. Solid samples (0.5 g) were introduced in
20 ml vials and loaded on a freeze-dryer (SMART LYO
Freeze Dryers). After thermal equilibration, the shelf tempera-
ture was lowered to 40 C. The product was maintained at
this temperature for 2 h. Then, the system was evacuated to
a pressure of 30 torr and the shelf temperature was adjusted
to 35 C and held for 4 h. Afterward, the shelf temperature
was raised successively to 20 C (8 h), then 0 C (8 h) and ﬁ-
nally 20 C (2 h). After drying the samples (5–6 mg), the vials
were capped within 5 min and stored at room temperature
(22–24 C) in a desiccator containing silica gel. The sample
was in the form of amorphous ﬂakes prepared by freeze-drying
and hence the particle size was not determined.2.6. Evaluation of solid dispersions and physical mixtures
2.6.1. Drug content determination
Drug: PVP-K30 solid dispersions and physical mixtures equiv-
alent to 10 mg of drug (CAN) in 10 ml of methanol, were ﬁl-
tered using a 0.45 lm ﬁlter paper, suitably diluted with
phosphate buffer (pH 6.8) and the drug content determined
using the calibration curve of pure drug in methanol by a
UV spectrophotometer (V-530, JASCO, Japan) at 255 nm
against phosphate buffer as blank. Experiments were done in
triplicate.
2.6.2. Saturation solubility studies
A saturation solubility study was carried out to determine the
increase in the solubility of pure drug compared with the phys-
ical mixture and solid dispersions. Excess amount of pure drug
(CAN) physical mixtures and solid dispersions were added to
10 ml of phosphate buffer (pH 6.8) in a 50 ml volumetric ﬂask.
Samples were stirred at 100 rpm temperature (37 C) in a
controlled water bath for 48 h. Samples were then ﬁltered
through 0.45 lm ﬁlters, suitably diluted and analyzed
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were done in triplicate.
2.7. Characterization of CAN: PVP-K30 (1:2) solid dispersions
2.7.1. Fourier Transform Infrared (FT-IR)
FT-IR is a useful tool to identify drug excipient interaction.
The spectra were obtained using a Fourier Transform Infrared
spectrometer (FTIR-8400, Shimadzu Corporation, Japan)
with a data station. About 2–3 mg of the sample was mixed
with dry potassium bromide (KBr) and the samples were
scanned from 4000 to 400 cm–1 with the resolution of 4 cm–1.
2.7.2. X-ray powder diffraction (XRPD)
XRPD analyses were performed for PVP-K30–pure drug
(CAN) physical mixtures and PVP-K30–pure drug (CAN) so-
lid dispersions using an X-ray diffractometer (PW 1729, Phi-
lips, Netherlands). The samples were irradiated with
monochromatized Cu Ka radiation (1.5406 A˚) and analyzed
between 5 and 50 2h. Voltage and current used were 40 kV
and 40 mA respectively. The range and the chart speed were
2 · 103 CPS and 10 mm/degree 2h, respectively.
2.7.3. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) has been a widely
used calorimetric tool to study the solid state interaction of
drug with PVP-K30. Modulated temperature DSC equipped
with an intracooler (DSC 60 Shimazdu, Japan) was used. In-
dium/zinc standards were used to calibrate the temperature
and enthalpy scale. The samples were heated in pierced alumi-
num pans at a rate of 10 C/min over a temperature range of
30–300 C. Inert atmosphere was maintained by purging nitro-
gen gas at a ﬂow rate of 40 ml/min.
2.7.4. Dissolution study
Dissolution studies were performed using a USP II Paddle dis-
solution apparatus (TDT-06P, Electrolab, India). To avoid
aggregation of powder in contact with the dissolution medium,
samples equivalent to 10 mg of pure drug (CAN) were mixed
with 10 g glass beads, dispersed in 5 ml dissolution medium
and then were placed in 900 ml phosphate buffer (pH 6.8)
maintained at 37 ± 0.5 C and stirred at 50 rpm. Samples were
collected periodically at 2, 4, 6, 8, 10, 15, 20, 25, and 30 min,
ﬁltered through a 0.45 lm ﬁlter paper and replaced with a
fresh dissolution medium. The concentrations were analyzed
spectrophotometrically at 255 nm. Drug release studies were
carried out in triplicate.
2.7.5. Preparation of the everted gut sacs
Freeze-dried solid dispersions of candesartan cilexetil (1:2 w/w)
were selected for the intestinal absorption study. The experi-
ments were carried out on male Sprague–Dawley rats (250–
270 g; 10–15-week-old) purchased from the National Institute
ofNutrition (NIN),Hyderabad.Theywere housed in large poly-
propylene cages with a 12-h light/dark cycle with free access to
water and maintained on commercial feed obtained locally.
After overnight fasting, the rats were anesthetized with ether
and the small intestine was isolated and rinsed with Tyrode buf-
fer solution (containing in mM: 15 glucose, 11.90 NaHCO3,
136.9 NaCl, 4.2 NaH2PO4, 2.7 KCl, 1.2 CaCl2 and 0.5 MgCl2)at room temperature and immediately placed at 37 C in an oxy-
genated (95% O2 and 5% CO2) Tyrode solution.
Brieﬂy, the intestinal segment was stripped off the adher-
ing tissue, washed with Tyrode solution and cut into small
sacs (3–4 cm in length). Each segment was gently everted
over a glass rod and ﬁlled with 0.5 ml of Tyrode buffer solu-
tion (pH 7.4) using a 1-ml plastic syringe and tied with a silk
suture at one end. The other end was connected to a small
cannula using silk suture. The rats were ﬁnally sacriﬁced with
overexposure to ether. The sacs were placed in 15 ml de-
gassed oxygenated Tyrode solution in an oscillating water
bath at 37 C in 20 ml capacity test tubes. One ml each of
four samples (each equivalent to 1 mg/ml of CAN in Tyrode
solution) – control (pure drug), pure drug with naringin
(15 mg/kg), and freeze-dried binary systems (1:2 w/w) with
and without naringin (15 mg/kg) were placed in respective
test tubes to ensure full exposure of the whole sac to the
drug and maintained at 37 C using a shaking water bath.
At the end of each time point i.e. 15, 30, 45, 60, 75, 90,
105 and 120 min, the corresponding everted sacs were re-
moved from the test tube, rinsed with Tyrode solution three
times, blotted dry and weighed. Then, the contents of the
sacs were collected and the sacs were weighed again to adjust
for the content volume. The experiments were repeated three
times (n= 3) and drug absorption was expressed as a
percentage.
All the animal experiments were performed in accordance
with the guidelines established by the Committee for the Pur-
pose of Control and Supervision on Experiments on Animals
(CPCSEA, New Delhi) and approved by the Institutional Ani-
mal Ethics Committee of Vaagdevi Institute of Pharmaceutical
Sciences, Warangal with registration number 1533/PO/a/11/
CPCSEA dated 7th April, 2012.2.8. Analytical method validation
RP-HPLC method was used to analyze the CAN samples in
phosphate buffer (pH 7.4). Validation was carried out for pre-
cision, linearity, speciﬁcity, accuracy, limit of quantiﬁcation
and ruggedness according to US Pharmacopoeia (FDA,
1997) and International Conference on Harmonization (ICH)
guideline ICH (Q2R1), 2007.2.8.1. HPLC sample analysis
The concentrations of CAN inside and outside the everted gut
sac were assayed using a Shimadzu HPLC system (LC – 20A
series) equipped with a UV detector, micro-volume double
plunger pump (10 ll/stroke) and manual injector type model
7725-port sample injection valve. The system was controlled
through SCL-10Avp or SCL-10A software. Samples from in-
side or outside the everted gut sac media were withdrawn, ﬁl-
tered through a 0.45l ﬁlter and 20 ll of samples were injected
into the HPLC system. HPLC analysis of samples was per-
formed under the following conditions: a Shim-pack VP-
ODS or equivalent ODS column (Particle size 5 lm, column
dimension: I.D 4.6 mm · length 150 mm) maintained at room
temperature; an isocratic mobile phase which consisted of ace-
tonitrile:methanol:water:glacial acetic acid (40:35:25:0.1 v/v/v/
v) at pH 6.8 respectively; and a ﬂow rate of 1 ml/min at ambi-
ent temperature. The detective wavelength was set at 255 nm.
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was made by measuring the peak areas to that of standard
peaks under the standard conditions. The analysis was
repeated three times (n= 3) to validate the obtained readings.
3. Data analysis
Data analysis was computed using SPSS version 19. The re-
sults were represented as mean ± standard deviation (±SD)
for all the experiments. The apparent permeability average val-
ues (Papp) were compared for each sample using one way anal-
ysis of variance (ANOVA) test. Student’s t-test was used to
compare drug diffusion data sets. The difference was consid-
ered signiﬁcant at p 6 0.05.Figure 1 Phase solubility analysis plot.3.1. Phase-solubility studies
The apparent stability constant, Ks was computed from the




The values of Gibbs free energy of transfer, DGotr, of candesar-
tan cilexetil from aqueous solution of the carrier (PVP-K30)
were calculated according to the relationship:
DGotr ¼ 2:303: log
So
Ss
where, So and Ss are the molar solubilities of pure drug in the
aqueous solution and the carrier respectively.
3.2. Dissolution efﬁciency (DE) studies
The drug release proﬁles were characterized by calculating the
dissolution efﬁciency (DE) of the samples. The dissolution efﬁ-
ciency of a pharmaceutical dosage form is deﬁned as the area
under the dissolution curve up to a time, t, expressed as a per-
centage of the area of the rectangle described by 100% disso-







where, y is the percent of drug released at time, t.
3.3. Calculation of the apparent permeability coefﬁcients
Apparent permeability coefﬁcient (Papp) was determined






where Papp (cm/s) is the apparent permeability coefﬁcient, dQ/
dt (mg/s) is the amount of drug transported across the mem-
brane per unit time, A (cm2) is the surface area available for
permeation and C0 (mg/ml) represents the initial concentration
of the drug outside the everted gut sacs. The mean and the
standard deviation values of Papp were calculated and ex-
pressed in 106 cm/s unit.3.4. Calculation of the percentage of drug recovery and drug
retained (Lassoued et al., 2011)
The percentage of drug recovery (R%) was calculated accord-
ing to Eq. (2):
R% ¼ Cr;end  Vm þ Cd;end  Vd
Cm  Vr  100 ð2Þ
where Cr,end and Cd,end (mg/ml) are the drug concentrations
measured at the end of the experiment inside and outside the
sacs respectively; C0 (mg/ml) is the initial concentration of
the drug outside the everted gut sacs; Vr and Vd (ml) are the
volumes of the mucosal and the serosal media respectively.
The percentage of drug retained (Ad %) on the intestinal
tissues was determined according to Eq. (3):
Ad% ¼ 100 R% ð3Þ
3.5. Water ﬂux measurement
The water ﬂux, resulting from both water absorption and ef-
ﬂux in the jejunum segment was determined according to the
following equation: (Park et al., 2011; Khemiss et al., 2009)
Water flux ¼ P3  P2
P1
where P1 is the weight of the empty and blotted sac, P2 is the
weight of the sac + 500 ll Tyrode solution (pH 7.4) and P3 is
the weight of the sac at the end of experiment. The water ﬂux
was determined after 2 h of experiment and the results were ex-
pressed in g water/g fresh intestine. Assays for the evaluation
of water ﬂux were repeated six times (n= 6).
4. Results and discussion
4.1. Phase solubility analysis
The phase solubility of candesartan cilexetil in the presence of
PVP-K30 is shown in Fig. 1. The apparent stability constant
(Ks) was found to be 179.1 m
1. An increase in solubility of
the drug was linear (r2 > 0.9) with an increase in concentra-
tion of polymer (0.2–2 lg/ml) in water showing an AL type sol-
ubility curve. Gibbs free energy change, DGotr values were all
negative at various PVP-K30 concentrations (0.2–2 lg/ml) as
shown in Table 1.
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solid dispersions
4.2.1. Drug content
Preliminary experiments by preparing physical mixtures and
solid dispersions using CAN and PVP-K30 in different drug-
to-carrier ratios showed maximum solubility with 1:2 drug to
polymer ratio. Hence, the ratio of CAN:PVP-K30 (1:2) was se-
lected for the study.
Percentage drug content of physical mixtures and solid dis-
persions was found within the range of 83–94% as shown in
Table 2. The maximum percent of drug content was found
to be 93.30 % in the freeze-dried complex.
4.2.2. Saturation solubility study
The saturation solubility of physical mixtures and solid disper-
sions is presented in Table 2. The freeze-dried solid dispersion
showed maximum saturation solubility (42.15 lg/ml).
4.3. Characterization of CAN:PVP-K30 (1:2) solid dispersions
and physical mixtures
4.3.1. FT-IR
Fig. 2 illustrates the FT-IR spectra of the samples under study.
The spectrum of candesartan cilexetil shows prominent peaks
at 2940, 2931, 1715, 1612, 1600, 1347 and 1281 cm1 corre-
sponding to C–H aromatic stretching, C–H aliphatic stretch-
ing, C‚O stretching in ester, C‚O stretching in acid, C‚N
aromatic stretching, C‚C aromatic, C–N and –C–O–ester.
The prominent peaks of PVP-K30 are at 2950, 1651, 1512
and 1270 cm1 corresponding to C–H aliphatic stretching,
C‚O stretching in acid, ‚C stretching and C–N stretching
respectively. Physical mixtures of CAN/PVP (Fig. 2C) exhib-
ited spectra corresponding to a superposition of their parent
components and a broad peak at 3390 cm1 (broad band).
In the spectra of all other prepared solid dispersion systemsTable 2 Percentage drug content and saturation solubility of drug:
Methods of preparation Drug content (%)
Pure drug –
Physical mixture 72 ± 0.6
Kneading 82 ± 0.53
Spray drying 90.2 ± 0.73
Freeze drying 93.3 ± 0.65
(Mean ± SD, n= 3).
Table 1 Gibbs free energy of transfer ðDGotrÞ for solubilization
process of CAN in aqueous solutions of PVPK30 at 37 C.






2 2.9(Fig. 2D and F), the characteristic peaks of PVP were present
at almost the same positions along with a broad peak at
3390 cm1. Moreover, all the spectra showed no peaks other
than those assigned to CAN and PVP.
4.3.2. Powder X-ray diffractometry [PXRD]
PXRD patterns of pure drug and CAN:PVP-K30 (1:2) physi-
cal mixtures and solid dispersions are shown in Fig. 3. The
powder X-ray diffractrograms of pure CAN exhibited charac-
teristic diffraction peaks at a diffraction angle of 2h at 9.94,
11.48, 14.42, 16.97, 18.93, 21.80, 22.82, 24.73, 27.48, and
29.17. The spectrum of PVP exhibited complete absence of
any diffraction peak, which is characteristic of an amorphous
compound. The diffractrograms of all prepared systems
showed peaks similar to PVP and absence of major diffraction
peaks corresponding to CAN. However, the diffractrograms of
CAN:PVP-K30 (1:2) freeze dried solid dispersions were found
to be more diffuse than other prepared systems showing no
characteristic peaks of pure drug.
4.3.3. Differential scanning calorimetry [DSC]
Thermograms of pure drug and CAN:PVP-K30 (1:2) physical
mixtures and solid dispersions are shown in Fig. 4. DSC stud-
ies showed the melting endothermic peak for pure CAN at
164.9 C, whereas the scan of PVP-K30 showed a broad endo-
therm ranging from 100 to 140 C due to the presence of resid-
ual moisture. The physical mixture thermogram showed an
exothermic peak at 210 C (due to recrystallization) and an
endothermic peak corresponding to superposition of their par-
ent components between 100 and 140 C (Fig. 4C). In the
curves of all other prepared systems of solid dispersions with
PVP (Fig. 4D and E), a very broad endotherm characteristic
of amorphous PVP between 100 and 150 C was noticed.
The thermogram of CAN:PVP-K30 (1:2) freeze dried solid dis-
persions showed a drastic shift in the endothermic peak of
PVP-K30 and complete disappearance of peaks of the pure
drug (Fig. 4F).4.3.4. In vitro release proﬁle of complexes
Dissolution proﬁles of pure drug, and all other prepared sys-
tems (SDs and PMs) were carried out in phosphate buffer
(pH 6.8) as shown in Fig. 5. DP30 min values (percent drug
dissolved within 30 min) and t50 % (time to dissolve 50%
drug) values for different samples are reported in Table 3.
From data presented in Table 3 and Fig. 5, it is evident that
the dissolution rate of pure drug is very low. Solid disper-
sions of CAN with PVPK30 (1:2) by the freeze-drying meth-
od signiﬁcantly enhanced the dissolution rate of CAN (80–
85%) as compared to pure drug and all other preparedPVPK30 (1:2).
Saturation solubility (lg/ml) % Increase in solubility
4.56 ± 0.23 –
17.92 ± 1.05 392.98
22.3 ± 1.45 489.03
33.2 ± 1.89 728.07
42.5 ± 2.31 932.01
Figure 2 FT-IR spectra of single component and binary systems of CAN and PVPK30, physical mixture, kneading, spray dried and
freeze dried. (A) CAN, (B) PVPK30, (C) physical mixture, (D) kneading, (E) spray drying, and (F) freeze drying (top to bottom).
252 S. Gurunath et al.systems. Percent of drug dissolved at 10 and 30 min was
highest in magnitude for solid dispersions prepared by the
freeze drying technique than all other prepared systems.
Freeze dried binary systems showed maximum enhancement
in dissolution rate (DE30 = 80.4%).Figure 3 PXRD diffractrograms of single components and
binary systems of CAN and PVPK30, physical mixture, kneading,
spray dried and freeze dried. (A) CAN, (B) PVPK30, (C) physical
mixture, (D) kneading, (E) spray drying, and (F) freeze drying.4.3.5. Permeability studies
Preliminary experiments of the everted gut sac apparent per-
meability studies showed the maximum permeability coefﬁ-
cient, Papp (cm/s) for naringin at 15 mg/kg over other
concentrations i.e. 5 and 10 mg/kg, respectively. Hence, the
highest concentration of naringin (15 mg/kg) was selected for
the study. The everted gut sac apparent permeability coefﬁ-
cients, Papp (cm/s) of CAN alone; CAN+ naringin (15 mg/
kg); CAN–PVP-K30 binary systems (freeze dried solid disper-
sion) at drug: polymer weight ratio (1:2 w/w) with and without
naringin (15 mg/kg) across the everted gut sac are shown in
Table 4. Data are expressed as mean ± SD and results are ex-
pressed in cm/s.
The apparent permeability value (Papp) of CAN was
0.76 ± 0.08 · 106 cm/s. Although CAN–PVP-K30 binary
systems (Freeze dried solid dispersions) with and without
naringin (15 mg/kg) showed a signiﬁcant increase in apparent
permeability coefﬁcients (P< 0.05) when compared with
Figure 4 DSC thermograms of single component and binary systems of CAN and PVPK30, physical mixture, kneading, spray dried and
freeze dried. (A) CAN, (B) PVPK30, (C) physical mixture, (D) kneading, (E) spray drying, and (F) freeze drying (top to bottom).
Figure 5 Cumulative percent of drug release from pure drug and prepared systems.
Table 3 Percent drug dissolved within 30 min (DP30 min),
time to dissolve 50% drug (T50%) for pure CAN and its
prepared systems.
Methods of preparation DP30 min T50 (min)
CAN 6.57 >30
Physical mixture 9.09 >30
Kneading method 9.72 >30
Spray drying 49.5 30
Freeze drying 80.4 10
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(12.40 ± 2.12 · 106 cm/s) were found with freeze dried solid
dispersions in the presence of naringin (15 mg/kg). However,
the Papp coefﬁcient of freeze dried solid dispersion (1:2; w/w)
in the absence of P-gp inhibitors (naringin) was
3.99 ± 2.01 · 106 cm/s (Fig. 6).
4.3.6. Percentage of drug recovery and drug retained
determination
The percentages of drug recovery (R %) and drug retention
(Ad %) of CAN; CAN+ naringin (15 mg/kg); CAN–
Table 4 Apparent permeability coefﬁcients Papp (cm/s) and percentages of drug recovery and drug retention for CAN in the presence
of naringin across the everted gut sac model.
In-vitro absorption model Sample Percentage of drug
recovery ± S.Da (%)
Percentage of drug
retention ± S.Da (%)
Papp (·106 cm/s)
Everted Sac technique CAN (control) 91.35 ± 1.84 8.65 ± 1.84 0.75 ± 0.08
CAN+Naringin (15 mg/kg) 91.65 ± 1.63 8.35 ± 1.63 3.40 ± 0.14
CAN freeze dried solid dispersions (1:2 w/w) 93.35 ± 1.72 6.65 ± 1.72 3.99 ± 2.01
CAN freeze dried solid dispersions (1:2 w/w)
+ Naringin (15 mg/kg)
96.05 ± 1.61 3.95 ± 1.61 12.40 ± 2.12
a Data are presented as mean ± SD; (n= 3).
254 S. Gurunath et al.PVP-K30 binary systems (Freeze dried) at drug: polymer
weight ratio 1:2 (w/w) with or without naringin (15 mg/kg)
across the everted gut sac model is shown in Table 4. The per-
centages of drug retention on the intestinal barrier were below
10% for all experiments.
4.3.7. Water ﬂux studies
During all the experiments a transfer of water molecules from
outside (mucosal side) to inside (serosal side) the everted gut
sacs was noticed, demonstrating absorption expressed in g
water/g fresh intestine. A signiﬁcant increase in water inﬂux
(P< 0.05) was aggravated after the addition of naringin
(15 mg/kg) in the mucosal medium. Water ﬂux results forFigure 7 Water ﬂux of pure drug and prep
Figure 6 Apparent permeability coefﬁcients Papp (cm/s) of puCAN–PVP-K30 binary systems were 1.35 ± 0.21 g water/g
fresh intestine for freeze dried solid dispersion with naringin
as shown in Fig. 7.5. Discussion
In this study, we attempted to enhance the intestinal absorp-
tion of candesartan cilexetil by improving its solubility, modu-
lating the physicochemical nature into the amorphous form
and inhibiting P-gp efﬂux transporters. The solubility of can-
desartan cilexetil increased owing to dispersion of the drug
in PVP-K30. A Gibbs free energy change indicated theared systems in the presence of naringin.
re drug and prepared systems in the presence of naringin.
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the reaction was favorable with increase in the concentration
of PVP-K30. This may probably be because of soluble com-
plexes between water-soluble polymeric carrier and poorly sol-
uble drug. The improved solubility is attributed to the
wettability of PVP-K30 forming an intermolecular hydrogen
bond between CAN and PVP-K30 and a decrease of the inter-
facial tension between the drug and the aqueous medium. The
freeze-dried solid dispersion showed maximum amount of
drug content and saturation solubility than other formulations
due to amorphous nature of the drug in PVP-K30. Thus,
enhancement of solubility for CAN in 1:2 ratio was 10.1-fold
at 37 C by PVPK30. The chemical interaction between drug
and PVP-K30 offers insights into the changes in the infrared
proﬁles of dispersions. It was noted that the acid carbonyl
stretching bend of CAN shifted from 1715 cm1 toward lower
frequencies (1713 cm1) which might be attributed to intermo-
lecular hydrogen bonding between CAN and >N– and C‚O
of PVP-K30. Moreover, the absorption band at 3390 cm1 was
broadened which attributed to the presence of water conﬁrm-
ing the broad endotherm detected in the DSC experiments.
Thus, IR spectra did not reveal dramatic changes in character-
istic peaks of CAN molecule dispersed into the matrices of
PVP-K30 suggesting the absence of well deﬁned chemical
interactions between the drug and the polymer. The assessment
of degree of crystallinity of the sample is done by Powder X-
ray diffraction spectroscopy. The complete dispersion of drug
and PVP-K30 reduces the number of crystalline structures or
appearance of halo at the baseline indicating amorphousness
of the drug in the given sample. The diffractrograms were
found to be more diffuse compared to the pure drug without
characteristic peaks indicating the formation of amorphous so-
lid state. Thus, the ﬁnal product sample (freeze dried) demon-
strated fewer and diffuse peaks, signifying an increase in
solubility and drug release. DSC enables quantitative endo-
thermic or exothermic phase transformations of drug in the gi-
ven sample demonstrating complete dispersion of pure drug
within the matrices of PVP-K30. The characteristic features
of CAN peak were lost. This indicated that CAN was no long-
er present as a crystalline material, but was converted into the
amorphous state. DSC thermogram of solid dispersions
(Fig. 4) presented a straight line with absence of any thermo-
dynamic transitions. In DSC thermogram of a freed dried pre-
pared system, no distinct glass transition (Tg) was evident till
290 C (Fig. 4F). In the amorphous form, there was no indica-
tion of Tg in DSC suggesting that CAN is a good glass former
and requires more sensitive techniques to determine its Tg. The
absence of melting peak clearly indicated the existence of the
amorphous state of drug, which was also conﬁrmed by XRPD
(Fig. 3) showing a halo, characteristic of amorphous form. The
DSC scan of all formulations shows a broad melting endo-
therm between 100 and 140 C indicating loss of water from
PVP-K30 followed by diminishing or absence of a drug peak.
Thus, DSC studies conﬁrmed that the drug is present as a solid
solution inside the PVP-K30 matrix of freeze dried product.
Extent of solubility and dissolution was found to show a rela-
tionship with particle size of binary prepared systems. It was
seen that the particle size range (150 and 250 lm) for physical
mixtures and solid dispersions prepared by kneading method
and spray drying were responsible for lower dissolution. How-
ever, powder dissolution of spray and freeze dried prepared
systems shows improved dissolution over physical mixturesand kneading method, because the highly water soluble PVP-
dispersion of the drug may have resulted in rapid dissolution
of spray dried solid dispersions. Nevertheless, freeze dried pre-
pared samples contain a lower particle size <38 lm diameter
and amorphous ﬂakes and hence shows faster dissolution.
The increase in drug release in freeze dried solid dispersions
is due to the dispersion effect of the hydrophilic carrier and
lowering of surface tension of the dissolution medium (Galia
et al., 1999). Freeze dried solid dispersion presented dramatic
improvements in the rate as well as the extent of drug release
(Fig. 5) and presented highest drug release (80% drug released
in 30 min). In the early 5 min period, there was about 5-fold
increase of drug release from freeze dried solid dispersion com-
pared to pure CAN. This improved drug release attributed to
the presence of amorphous form of CAN, as conﬁrmed by
DSC and PXRD studies. Other factors such as increased wet-
tability, solubilization of the drug by the carrier at the diffu-
sion layer, and the reduction or absence of aggregation and
agglomeration increased the rate of dissolution.
Based on all of the above ﬁndings, the possible mechanisms
for an increased release rate from solid dispersions have been
postulated and are summarized as follows: (i) reduction of
crystallinity (ii) increased water absorption by the hydrophilic
carrier which leads to increased wettability (iii) solubilization
effect by the carrier and (iv) phase transition from crystalline
to amorphous nature.
Candesartan cilexetil absorption assessment was performed
with the in vitro everted gut sac model prepared from rat jeju-
num. (Bohets et al., 2001; Wang et al., 2007) The technique is a
simple and economical method. It is an efﬁcient tool to assess
P-gp’s role in the intestinal absorption of drug compounds.
The validity of this technique can be explained by histological
studies. Histological slides observed under light microscopy
after 120 min of experiment showed that the intestine remained
intact morphologically with microvillosities and intact brush
border (Lassoued et al., 2011). We investigated the effect of
naringin, a natural ﬂavonoid in grape fruit on candesartan
absorption at 15 mg/kg. Permeability studies were undertaken
for pure CAN; CAN+ naringin and CAN–PVP-K30 binary
systems (Freeze dried product) in the absence or presence of
P-gp inhibitors (naringin). We noted a signiﬁcant (P< 0.05)
enhancement of CAN permeability compared with pure drug
alone (13.87-fold). This enormous increase may have been
attributed to the solubility improvement of CAN in the amor-
phous form as solid dispersions (Weuts et al., 2003). The addi-
tion of naringin in the mucosal medium signiﬁcantly
(P< 0.05) increased the permeability values by 14.99-fold of
the drug in freeze dried solid dispersions compared to the per-
meability values of the drug in freeze dried solid dispersions
without naringin in the mucosal medium. This could be attrib-
uted to the inhibitory effect of naringin on the P-gp efﬂux
transporter indicating that candesartan may be a substrate
for P-gp5 and the intestinal cytochrome P450 (CYP) 3A4 iso-
enzyme activity (Choi and Han, 2005).
In this study, it is indicated that the intestinal absorption of
freed dried solid dispersion was better than that of pure drug
alone. There was signiﬁcant difference in intestinal absorption
between solid dispersion and pure drug (p < 0.05) and insig-
niﬁcant difference between pure drug and pure drug + narin-
gin (p > 0.05). Therefore, it is inferred that CAN is dispersed
in the carrier greatly and was ready to absorb from the intes-
tinal medium. The improvement of intestinal absorption was
256 S. Gurunath et al.attributed to the physical characteristics of CAN in solid dis-
persion, but not because of the simple effect of excipients
(PVP K30) Cheng et al., 2010.
In this study, we also demonstrated the water ﬂux for CAN
alone; CAN+ naringin and CAN–PVP-K30 binary systems
in the presence and absence of P-gp inhibitors (naringin). We
found that there was a transfer of water from the outside to
the inside of the sacs in the presence of P-gp inhibitor, which
translated as complete absorption than in the absence of narin-
gin. The comparison at the end of the assays (after 120 min)
showed that the water ﬂux was greater for CAN–PVP-K30
freeze dried solid dispersions (P< 0.05) with P-gp inhibitor
than without P-gp inhibitor. This could be explained by the fact
that the absorption of CAN might be resulted by the inhibition
of intestinal efﬂux transporter P-gp as previously reported for
intestinal absorption of digoxin concerning the role of P-gp
where the water absorption increased signiﬁcantly in the duode-
numand the jejunumwith verapamil, a P-gp inhibitor by Sababi
et al. (2001). During permeation experiments undertaken with
the everted gut sacmodel, it was important to assess the percent-
ages of CAN recovery (R%) outside and inside the sacs and the
percentage of CAN retained (Ad%) on the intestinal tissue. The
results showed that the values forR%were above 90%, indicat-
ing that the amount of drug retained by the everted gut sac tis-
sues was very less. This phenomenon may have been due to the
accumulation of drug into the muscular layer as reported previ-
ously (Park et al., 2011) during the passage from mucosal to
serosal side on the everted gut sac.
6. Conclusion
Solubility, dissolution and permeability are the fundamental
triad governing the oral drug absorption and their enhance-
ment remains the most challenging job for pharmaceutical sci-
entists. Low drug solubility manifests many in vivo limitations
like incomplete release from the dosage form, poor bioavail-
ability, increased food effect and higher inter-patient variabil-
ity. CAN being a lipophilic molecule, practically insoluble in
water and a substrate of P-glycoprotein, could potentially
demonstrate solubility and permeability limited bioavailabil-
ity. Therefore, high energy amorphous forms as freeze dried
solid dispersions may be useful for such lipophilic drugs where
solubility is dependent on hydrophilic forces of a carrier, and
disruption of crystal lattice may result in enhanced solubility.
Therefore, the current study suggests that on enhancement of
aqueous solubility with high energy amorphous forms and
inhibition of efﬂux transporters using naringin, which are
capable of mediating the absorption of CAN, the oral bio-
availability can be enhanced. Therefore, naringin could be
used as a pharmaceutical excipient in candesartan cilexetil so-
lid dispersions to increase its intestinal absorption and oral
bioavailability.
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